ORIGINAL ARTICLE
Ahead of Print

The performance of 18F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis


1 Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
2 Department of Urology, Yancheng Third People's Hospital, Yancheng 224000, China
3 Department of Urology, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng 224000, China

Correspondence Address:
Rui-Peng Jia,
Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aja202162

PMID: 34747721

This paper presents a meta-analysis regarding the detection rate (DR) of fluorine-18 (18F)-labeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in the management of patients with prostate cancer (PCa). Relevant studies regarding 18F-PSMA PET/CT in the management of PCa published until June 1, 2021, were electronically searched in online databases including EMBASE, PubMed, and Web of Science. The primary outcome was the DR of 18F-PSMA PET/CT in managing PCa patients, while the secondary outcome was the DR of 18F-PSMA PET/CT according to Gleason scores and serum prostate-specific antigen (PSA) level. The pooled DR was calculated on a per-patient basis, with pooled odd ratios and 95% confidence intervals (CIs). In total, 17 observational studies evaluating 1019 patients with PCa met the inclusion criteria. The DR of 18F-PSMA PET/CT was 0.83 (95% CI: 0.78–0.88), in the random-effects model. Subsequently, the analysis of DR of 18F-PSMA PET/CT in PCa patients using Gleason score (≤7 vs ≥8), showed a significant difference in PCa patients. Based on the above results, the higher Gleason score of PCa patients, the higher DR of 18F-PSMA PET/CT. The DR of 18F-PSMA PET/CT in PCa was 0.57 for PSA <0.5 ng ml−1; 0.75 for PSA ≥0.5 ng ml-1 and <1.0 ng ml-1; 0.93 for PSA ≥1.0 ng ml-1 and <2.0 ng ml-1; and 0.95 for PSA ≥2.0 ng ml−1. Therefore, the significant diagnostic value was found in terms of the DR of 18F-PSMA PET/CT in managing PCa patients and was associated with Gleason score and serum PSA level.


[FULL TEXT] [PDF]
Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Qin ZQ
    -  Pan GJ
    -  Xu Z
    -  Wang H
    -  Xu LW
    -  Jia RP
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed532    
    PDF Downloaded36    

Recommend this journal